{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:16:05Z","timestamp":1773281765939,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009874","name":"Universit\u00e9 de Sherbrooke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009874","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004888","name":"Centre Hospitalier Universitaire de Qu\u00e9bec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004888","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008237","name":"Department of Surgery","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008237","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.jcjo.2018.04.017","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T21:08:27Z","timestamp":1529615307000},"page":"223-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Randomized crossover trial comparing effectiveness and tolerability of generic and brand-name travoprost"],"prefix":"10.1016","volume":"54","author":[{"given":"David","family":"Ta Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Daigle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjorie","family":"Carbonneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2018.04.017_bib1","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjo.2005.081224","article-title":"The number of people with glaucoma worldwide in 2010 and 2020","volume":"90","author":"Quigley","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2018.04.017_bib2","first-page":"701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol Chic Ill 1960"},{"issue":"Suppl 1","key":"10.1016\/j.jcjo.2018.04.017_bib3","first-page":"S7","article-title":"Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye","volume":"44","year":"2009","journal-title":"Can J Ophthalmol"},{"issue":"Suppl.1","key":"10.1016\/j.jcjo.2018.04.017_bib4","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.survophthal.2008.08.012","article-title":"Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences","volume":"53","author":"Bean","year":"2008","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jcjo.2018.04.017_bib5","series-title":"Notice: Guidance for Industry: Pharmaceutical Quality of Aqueous Solutions","year":"2005"},{"key":"10.1016\/j.jcjo.2018.04.017_bib6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jcjo.2011.12.004","article-title":"Generic versus brand-name North American topical glaucoma drops","volume":"47","author":"Mammo","year":"2012","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jcjo.2018.04.017_bib7","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11606-010-1513-8","article-title":"Understanding equivalence and noninferiority testing","volume":"26","author":"Walker","year":"2011","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jcjo.2018.04.017_bib8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/BF01068419","article-title":"A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability","volume":"15","author":"Schuirmann","year":"1987","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.jcjo.2018.04.017_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5301\/ejo.5000041","article-title":"Latanoprost 0.005% test formulation is as effective as Xalatan\u00ae in patients with ocular hypertension and primary open-angle glaucoma","volume":"22","author":"Allaire","year":"2012","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jcjo.2018.04.017_bib10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/0301-4738.30707","article-title":"A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic Latanoprost (Latoprost) in subjects with primary open-angle glaucoma or ocular hypertension","volume":"55","author":"Narayanaswamy","year":"2007","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jcjo.2018.04.017_bib11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/1440-1681.12329","article-title":"Original and generic latanoprost for the treatment of glaucoma and ocular hypertension: are they really the same?","volume":"42","author":"Golan","year":"2015","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.jcjo.2018.04.017_bib12","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/IJG.0b013e318259b47c","article-title":"An evaluation of therapeutic noninferiority of 0.005% latanoprost ophthalmic solution and xalatan in patients with glaucoma or ocular hypertension","volume":"22","author":"Digiuni","year":"2013","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jcjo.2018.04.017_bib13","unstructured":"Urbaniak GC, Plous S. Research randomizer 2013. Available from: https:\/\/www.randomizer.org\/ Accessed February 11, 2018."},{"key":"10.1016\/j.jcjo.2018.04.017_bib14","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ophtha.2017.05.024","article-title":"Brand medications and Medicare Part D: how eye care providers\u2019 prescribing patterns influence costs","volume":"125","author":"Newman-Casey","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2018.04.017_bib15","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jcjo.2016.05.014","article-title":"Preservative content in generic and brand name glaucoma eye drops","volume":"51","author":"Hallaji","year":"2016","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jcjo.2018.04.017_bib16","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1111\/aos.12321","article-title":"Comparison of intraocular pressure in glaucoma subjects treated with Xalatan versus generic latanoprost","volume":"92","author":"Egan","year":"2014","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"10.1016\/j.jcjo.2018.04.017_bib17","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/aos.13355","article-title":"The physical properties of generic latanoprost ophthalmic solutions are not identical","volume":"95","author":"Kolko","year":"2017","journal-title":"Acta Ophthalmol Scand Suppl"},{"key":"10.1016\/j.jcjo.2018.04.017_bib18","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/IJG.0000000000000506","article-title":"Squeeze me if you can: variability in force requirements to extract a drop from common glaucoma bottles","volume":"25","author":"Moore","year":"2016","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jcjo.2018.04.017_bib19","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jcjo.2016.04.027","article-title":"Generic glaucoma drop bottle cap colours","volume":"51","author":"Hallaji","year":"2016","journal-title":"Can J Ophthalmol"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418218301704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418218301704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T17:23:40Z","timestamp":1762104220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418218301704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0008418218301704"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2018.04.017","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized crossover trial comparing effectiveness and tolerability of generic and brand-name travoprost","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2018.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}